Search Results 1101-1110 of 18519 for Prednisone

1. A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Efficacy and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow® Device plus Standard of Care versus Standard of Care Alone in the Treatment of Chronic Lung Allograft Syndrome / Bronchiolitis Obliterans Syndrome in Patients post Double Lung Transplantation (BOSTON-2) - Mayo Clinic

   systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic ...

2. Study Evaluating the Safety and Effectiveness of JCARH125 in Subjects with Relapsed and/or Refractory Multiple Myeloma (EVOLVE) - Mayo Clinic

   Therapeutic doses of corticosteroids (defined as > 20 mg/day prednisone or equivalent) within 14 days before leukapheresis. Physiologic replacement, topical ...

3. Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma - Mayo Clinic

   Requires immunosuppressive doses of corticosteroid therapy (>10 mg/day prednisone equivalents) for ≥ 2 weeks prior to registration. Active, known, or ...

4. A Dose Escalation Study of HFB301001 in Adult Patients with Advanced Solid Tumors - Mayo Clinic

   ... prednisone or equivalent) or any immune suppressive therapy. - Persisting toxicity of >Grade 1 relating to prior anti cancer therapy with the following ...

5. IFX_HU2.0 As An Adjunctive Therapy To Pembrolixumab In Checkpoint Inhibitor Naive Subjects With Advanced Or Metastatic Merkel Cell Carcinoma - Mayo Clinic

   A condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days ...

6. Study Of The Bria-IMT Regimen And CPI Vs Physicians' Choice In Advanced Metastatic Breast Cancer. (BRIA-ABC) - Mayo Clinic

   Have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses exceeding 10 mg daily of prednisone equivalent) or any other ...

7. Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes - Mayo Clinic

   Chronic use, as defined by > 2 weeks of a corticosteroid agent that is ≥ 20 mg/day of prednisone or its equivalent, within 4 weeks prior to first ...

8. Divalproex sodium (oral route) - Side effects & dosage - Mayo Clinic

   Divalproex sodium is also used to treat the manic phase of bipolar disorder (manic-depressive illness) and helps prevent migraine headaches. This medicine is ...

9. A Study to Evaluate the Effectiveness of M7824 Monotherapy in Locally Advanced or Metastatic Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) - Mayo Clinic

   ... prednisone or equivalent per day;; Administration of steroids for other conditions through a route known to result in a minimal systemic exposure (topical ...

10. Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer - Mayo Clinic

    ... prednisone or equivalent per day) or other immune suppressive drugs within 2 weeks of first study drug administration; Trauma or major surgery within 4 weeks ...